ConvaTec Group (LON:CTEC) Receives “Buy” Rating from Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of ConvaTec Group (LON:CTEC) in a research note issued to investors on Tuesday morning,Digital Look reports. They currently have a GBX 340 price objective on the stock.

Several other brokerages have also issued reports on CTEC. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, April 8th. Citigroup restated an “outperform” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and set a GBX 325 target price on shares of ConvaTec Group in a research report on Friday, April 10th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, March 11th. Nine investment analysts have rated the stock with a Buy rating, According to MarketBeat, ConvaTec Group has a consensus rating of “Buy” and an average price target of GBX 319.67.

ConvaTec Group Stock Down 1.1%

Shares of LON:CTEC opened at GBX 234.20 on Tuesday. ConvaTec Group has a 1 year low of GBX 209.40 and a 1 year high of GBX 311.20. The business has a 50 day simple moving average of GBX 231.90 and a two-hundred day simple moving average of GBX 235.11. The firm has a market capitalization of £4.58 billion, a PE ratio of 27.23, a price-to-earnings-growth ratio of 0.93 and a beta of 0.84. The company has a debt-to-equity ratio of 106.19, a current ratio of 1.53 and a quick ratio of 0.96.

Insider Buying and Selling at ConvaTec Group

In other news, insider Jonny Mason sold 291,149 shares of ConvaTec Group stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of GBX 234, for a total transaction of £681,288.66. Corporate insiders own 0.95% of the company’s stock.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.